Pepticom

Novel Peptide Drug Candidates

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in December 2011 by Immanuel Lerner, Anwar Rayan, and Amit Michaeli, Pepticom operates with 11–50 employees. The company has raised $14.2 million across 4 funding rounds from 3 investors. In January 2025, Pepticom successfully completed a Series A1 funding round, with The Chartered Group participating.

Business overview

Pepticom is a biotechnology company that leverages artificial intelligence to accelerate peptide drug discovery. Its proprietary algorithmic platform integrates economic and molecular mechanics principles to design a broad spectrum of active molecules, aiming to reduce the time and cost associated with traditional lab-based discovery methods. The platform can address complex protein targets and design various peptide chemistries, including linear, helical, and cyclic peptides, incorporating D and non-natural amino acids. Pepticom serves the pharmaceutical and biotechnology industries, focusing on drug discovery and development within the Health Tech & Life Sciences sector.

Strategic signal

In March 2021, Pepticom established PeptiCov, a spin-off company dedicated to developing treatments for the SARS-CoV-2 virus. This strategic move highlights Pepticom's agility in responding to global health crises and demonstrates the adaptability of its AI-driven peptide discovery platform to address urgent medical needs, signaling potential for rapid therapeutic development in emerging disease areas.

Log in to access full profile

Company Intelligence Q&A

What was a significant recent funding event for Pepticom?
In January 2025, Pepticom successfully completed its Series A1 funding round. The Chartered Group was a lead investor in this round.
What is Pepticom's core technology?
Pepticom utilizes an AI-driven algorithmic platform that combines economic and molecular mechanics principles to design novel peptide drug candidates at atomic resolution, streamlining the drug discovery process.
What strategic initiative did Pepticom undertake in response to the COVID-19 pandemic?
In March 2021, Pepticom established a spin-off company named PeptiCov, dedicated to developing treatments for the SARS-CoV-2 virus responsible for the COVID-19 outbreak.
When was Pepticom founded and by whom?
Pepticom was founded in December 2011 by Immanuel Lerner, Anwar Rayan, and Amit Michaeli.
Log in to access full profile